A new therapy targeting telomerase in glioblastoma treatment
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
This study is exploring a new treatment for glioblastoma using a drug called 6-thio-2'-deoxyguanosine, which aims to help your immune system fight the tumor by targeting a specific enzyme that’s often too active in these cancer cells, and it’s being developed with the help of experts to make it safer and more effective for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10919205 on NIH RePORTER |
What this research studies
This research investigates a novel treatment for glioblastoma, a highly aggressive brain tumor, using a drug called 6-thio-2'-deoxyguanosine. The approach focuses on targeting telomerase, an enzyme that is often overactive in glioblastoma cells, to induce tumor regression. The study involves both pre-clinical models and potential clinical trials to assess how this drug can stimulate immune responses against the tumor. By collaborating with experts from Duke University and UT Southwestern, the research aims to develop a more effective and less toxic treatment option for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking new treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, targeted therapy that improves survival rates and quality of life for glioblastoma patients.
How similar studies have performed: Previous research has shown promise in targeting telomerase for cancer treatment, suggesting that this approach could lead to significant advancements in glioblastoma therapy.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Ashley, David M. — Duke University
- Study coordinator: Ashley, David M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.